Literature DB >> 28584452

State of the Globe: Hepatitis C - Opportunistic versus Organized Screening.

Sunil Kumar Raina1, Vivek Chauhan2, Suman Thakur3.   

Abstract

Entities:  

Year:  2017        PMID: 28584452      PMCID: PMC5452548          DOI: 10.4103/jgid.jgid_71_17

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Saini et al. have reported a rise in hepatitic C virus (HCV) infection rate among the blood donors in Central India.[1] HCV-related deaths per year are on the rise. The 2015 Global Burden of Disease study showed that the estimated number of deaths due to hepatitis C in 1990 and 2013 was 333,000 and 704,000, respectively.[23] This indicates that there is a continuous increase in incident cases of hepatitis C, which may be largely attributable to the increased use of parenteral preparation and injection drug use.[4] Although with the universal screening of blood for HCV, a decline in incidence has been observed, still a large number of cases of hepatitis C continue to suffer from HCV-related cirrhosis and hepatocellular carcinoma.[5] The global resurgence in HCV cases has been noticed, especially in injection drug users and HIV-infected men who have sex with men.[67] A systematic review in 2013 estimates that about 184 million persons have a history of HCV infection (anti-HCV antibody) and about 130–150 million out of these may have chronicity (HCV RNA positive).[8] Although the recent reviews may point toward a lower prevalence, the number of people needing treatment for complications of HCV remains quite high.[9] A 5-year data analysis on the seroprevalence of transfusion-transmitted infections among blood donors in an Indian setting revealed that though the prevalence had decreased over a 5-year period but was still significant.[10]

RECOMMENDATIONS ON SCREENING

Two strategies for screening have been in use: first one uses organized screening programs (through mass or high-risk screening programs) to identify people with HCV infection and the second approach is that of opportunistic screening. Opportunistic screening is easy and sustainable; the organized screening needs the establishment of services at various health-care delivery setups with uniform standards and may not be financially viable. As it is obvious from the estimates derived till now, a large number of people will have to be invited to take part in these organized screening programs to be successful. The opportunistic screening for HCV can be conducted as and when someone asks for it or it can be offered at the time of blood testing for some other purposes. Unlike an organized screening program, opportunistic screening need not be monitored, and the cost will be minimal. Since we all seek or receive a health test or checkup in our lifetimes, the yield from such opportunistic screening programs will be substantial. As an early guideline for conducting opportunistic screening, the World Health Organization list on populations with a high HCV prevalence or a history of HCV risk exposure/behavior will be useful.[11] Any individual who received medical or dental interventions in health-care settings with below standard infection control practices Any individual who has received blood transfusions before serological testing of blood donors for HCV was initiated Any individual who has received blood transfusions in a country where serological testing of blood donations for HCV is not routinely performed People who inject drugs Any individual who have had tattoos, body piercing, or scarification procedures in a setting where infection control practices are below standard Children born to mothers infected with HCV HIV-infected individuals Individuals use/using/have used intranasal drugs Prisoners and previously incarcerated persons.
  10 in total

1.  The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.

Authors:  H Razavi; I Waked; C Sarrazin; R P Myers; R Idilman; F Calinas; W Vogel; M C Mendes Correa; C Hézode; P Lázaro; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; A J Blasco; C E Brandão Mello; P Bruggmann; M Buti; J L Calleja; H Cheinquer; P B Christensen; M Clausen; H S M Coelho; M E Cramp; G J Dore; W Doss; A S Duberg; M H El-Sayed; G Ergör; G Esmat; K Falconer; J Félix; M L G Ferraz; P R Ferreira; S Frankova; J García-Samaniego; J Gerstoft; J A Giria; F L Gonçales; E Gower; M Gschwantler; M Guimarães Pessôa; S J Hindman; H Hofer; P Husa; M Kåberg; K D E Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; R T Marinho; P Marotta; S Mauss; C Moreno; K Murphy; F Negro; V Nemecek; N Örmeci; A L H Øvrehus; J Parkes; K Pasini; K M Peltekian; A Ramji; N Reis; S K Roberts; W M Rosenberg; F Roudot-Thoraval; S D Ryder; R Sarmento-Castro; D Semela; M Sherman; G E Shiha; W Sievert; J Sperl; P Stärkel; R E Stauber; A J Thompson; P Urbanek; P Van Damme; I van Thiel; H Van Vlierberghe; D Vandijck; H Wedemeyer; N Weis; J Wiegand; A Yosry; A Zekry; M Cornberg; B Müllhaupt; C Estes
Journal:  J Viral Hepat       Date:  2014-05       Impact factor: 3.728

Review 2.  Global epidemiology and genotype distribution of the hepatitis C virus infection.

Authors:  Erin Gower; Chris Estes; Sarah Blach; Kathryn Razavi-Shearer; Homie Razavi
Journal:  J Hepatol       Date:  2014-07-30       Impact factor: 25.083

Review 3.  Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.

Authors:  Khayriyyah Mohd Hanafiah; Justina Groeger; Abraham D Flaxman; Steven T Wiersma
Journal:  Hepatology       Date:  2013-02-04       Impact factor: 17.425

4.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

5.  Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015.

Authors:  Caitlin Conrad; Heather M Bradley; Dita Broz; Swamy Buddha; Erika L Chapman; Romeo R Galang; Daniel Hillman; John Hon; Karen W Hoover; Monita R Patel; Andrea Perez; Philip J Peters; Pam Pontones; Jeremy C Roseberry; Michelle Sandoval; Jessica Shields; Jennifer Walthall; Dorothy Waterhouse; Paul J Weidle; Hsiu Wu; Joan M Duwve
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-01       Impact factor: 17.586

6.  Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013.

Authors:  Gilles Wandeler; Marion Schlauri; Marie-Eve Jaquier; Janine Rohrbach; Karin J Metzner; Jan Fehr; Juan Ambrosioni; Matthias Cavassini; Marcel Stöckle; Patrick Schmid; Enos Bernasconi; Olivia Keiser; Luisa Salazar-Vizcaya; Hansjakob Furrer; Andri Rauch; V Aubert; M Battegay; E Bernasconi; J Böni; H C Bucher; C Burton-Jeangros; A Calmy; M Cavassini; G Dollenmaier; M Egger; L Elzi; J Fehr; J Fellay; H Furrer; C A Fux; M Gorgievski; H Günthard; D Haerry; B Hasse; H H Hirsch; M Hoffmann; I Hösli; C Kahlert; L Kaiser; O Keiser; T Klimkait; R Kouyos; H Kovari; B Ledergerber; G Martinetti; B Martinez de Tejada; K Metzner; N Müller; D Nadal; D Nicca; G Pantaleo; A Rauch; S Regenass; M Rickenbach; C Rudin; F Schöni-Affolter; P Schmid; J Schüpbach; R Speck; P Tarr; A Telenti; A Trkola; P Vernazza; R Weber; S Yerly
Journal:  Open Forum Infect Dis       Date:  2015-03-25       Impact factor: 3.835

7.  Seroprevalence of hepatitis B, hepatitis C, Human Immunodeficiency Virus surface, and syphilis among blood donors: A 6-year report from a sentinel site in Western Himalayas, India.

Authors:  Sujeet Raina; Sunil K Raina; Rashmi Kaul; Vandana Sharma
Journal:  Indian J Sex Transm Dis AIDS       Date:  2015 Jul-Dec

8.  Hepatitis C Virus: Unnoticed and on the Rise in Blood Donor Screening? A 5 Years Cross-sectional Study on Seroprevalence in Voluntary Blood Donors from Central India.

Authors:  Purti Agrawal Saini; Preeti Rihal Chakrabarti; Amit V Varma; Shankhini Gambhir; Gargi Tignath; Priyanka Gupta
Journal:  J Glob Infect Dis       Date:  2017 Apr-Jun

9.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Rafael Lozano; Mohsen Naghavi; Kyle Foreman; Stephen Lim; Kenji Shibuya; Victor Aboyans; Jerry Abraham; Timothy Adair; Rakesh Aggarwal; Stephanie Y Ahn; Miriam Alvarado; H Ross Anderson; Laurie M Anderson; Kathryn G Andrews; Charles Atkinson; Larry M Baddour; Suzanne Barker-Collo; David H Bartels; Michelle L Bell; Emelia J Benjamin; Derrick Bennett; Kavi Bhalla; Boris Bikbov; Aref Bin Abdulhak; Gretchen Birbeck; Fiona Blyth; Ian Bolliger; Soufiane Boufous; Chiara Bucello; Michael Burch; Peter Burney; Jonathan Carapetis; Honglei Chen; David Chou; Sumeet S Chugh; Luc E Coffeng; Steven D Colan; Samantha Colquhoun; K Ellicott Colson; John Condon; Myles D Connor; Leslie T Cooper; Matthew Corriere; Monica Cortinovis; Karen Courville de Vaccaro; William Couser; Benjamin C Cowie; Michael H Criqui; Marita Cross; Kaustubh C Dabhadkar; Nabila Dahodwala; Diego De Leo; Louisa Degenhardt; Allyne Delossantos; Julie Denenberg; Don C Des Jarlais; Samath D Dharmaratne; E Ray Dorsey; Tim Driscoll; Herbert Duber; Beth Ebel; Patricia J Erwin; Patricia Espindola; Majid Ezzati; Valery Feigin; Abraham D Flaxman; Mohammad H Forouzanfar; Francis Gerry R Fowkes; Richard Franklin; Marlene Fransen; Michael K Freeman; Sherine E Gabriel; Emmanuela Gakidou; Flavio Gaspari; Richard F Gillum; Diego Gonzalez-Medina; Yara A Halasa; Diana Haring; James E Harrison; Rasmus Havmoeller; Roderick J Hay; Bruno Hoen; Peter J Hotez; Damian Hoy; Kathryn H Jacobsen; Spencer L James; Rashmi Jasrasaria; Sudha Jayaraman; Nicole Johns; Ganesan Karthikeyan; Nicholas Kassebaum; Andre Keren; Jon-Paul Khoo; Lisa Marie Knowlton; Olive Kobusingye; Adofo Koranteng; Rita Krishnamurthi; Michael Lipnick; Steven E Lipshultz; Summer Lockett Ohno; Jacqueline Mabweijano; Michael F MacIntyre; Leslie Mallinger; Lyn March; Guy B Marks; Robin Marks; Akira Matsumori; Richard Matzopoulos; Bongani M Mayosi; John H McAnulty; Mary M McDermott; John McGrath; George A Mensah; Tony R Merriman; Catherine Michaud; Matthew Miller; Ted R Miller; Charles Mock; Ana Olga Mocumbi; Ali A Mokdad; Andrew Moran; Kim Mulholland; M Nathan Nair; Luigi Naldi; K M Venkat Narayan; Kiumarss Nasseri; Paul Norman; Martin O'Donnell; Saad B Omer; Katrina Ortblad; Richard Osborne; Doruk Ozgediz; Bishnu Pahari; Jeyaraj Durai Pandian; Andrea Panozo Rivero; Rogelio Perez Padilla; Fernando Perez-Ruiz; Norberto Perico; David Phillips; Kelsey Pierce; C Arden Pope; Esteban Porrini; Farshad Pourmalek; Murugesan Raju; Dharani Ranganathan; Jürgen T Rehm; David B Rein; Guiseppe Remuzzi; Frederick P Rivara; Thomas Roberts; Felipe Rodriguez De León; Lisa C Rosenfeld; Lesley Rushton; Ralph L Sacco; Joshua A Salomon; Uchechukwu Sampson; Ella Sanman; David C Schwebel; Maria Segui-Gomez; Donald S Shepard; David Singh; Jessica Singleton; Karen Sliwa; Emma Smith; Andrew Steer; Jennifer A Taylor; Bernadette Thomas; Imad M Tleyjeh; Jeffrey A Towbin; Thomas Truelsen; Eduardo A Undurraga; N Venketasubramanian; Lakshmi Vijayakumar; Theo Vos; Gregory R Wagner; Mengru Wang; Wenzhi Wang; Kerrianne Watt; Martin A Weinstock; Robert Weintraub; James D Wilkinson; Anthony D Woolf; Sarah Wulf; Pon-Hsiu Yeh; Paul Yip; Azadeh Zabetian; Zhi-Jie Zheng; Alan D Lopez; Christopher J L Murray; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis.

Authors:  Gkikas Magiorkinis; Emmanouil Magiorkinis; Dimitrios Paraskevis; Simon Y W Ho; Beth Shapiro; Oliver G Pybus; Jean-Pierre Allain; Angelos Hatzakis
Journal:  PLoS Med       Date:  2009-12-15       Impact factor: 11.069

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.